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The botulinum toxins (BTX), type A and type B by blocking vesicle acetylcholine release at neuro-muscular and neuro-
secretory junctions can result eﬃcacious therapeutic agents for the treatment of numerous disorders in patients requiring neuro-
rehabilitative intervention. Its use for the reduction of focal spasticity following stroke, brain injury, and cerebral palsy is provided.
AlthoughthereductionofspasticityiswidelydemonstratedwithBTXtypeAinjection,itsimpactontheimprovementofdexterity
and functional outcome remains controversial. The use of BTX for the rehabilitation of children with obstetrical brachial plexus
palsy and in treating sialorrhea which can complicate the course of some severe neurological diseases such as amyotrophic lateral
sclerosis and Parkinson’s disease is also addressed. Adverse events and neutralizing antibodies formation after repeated BTX
injections can occur. Since impaired neurological persons can have complex disabling feature, BTX treatment should be viewed as
adjunct measure to other rehabilitative strategies that are based on the individual’s residual ability and competence and targeted to
achieve the best functional recovery. BTX therapy has high cost and transient eﬀect, but its beneﬁts outweigh these disadvantages.
Future studies must clarify if this agent alone or adjunctive to other rehabilitative procedures works best on functional outcome.
1.Introduction
Botulinum toxins are some of the most potent poi-
sons present in nature produced by the anaerobic bac-
terium Clostridium Botulinum. Historically, these toxins
were predominantly associated with a food-borne toxicosis
producing a neurological life-threatening disease called
“botulism”, characterized by a severe generalized muscular
paralysis and cholinergic autonomic blockade. Currently,
botulinum toxins have become established as eﬃcacious
therapeutic agents for the treatment of numerous medical
disorders. Seven types of toxins have been harvested from
clostridium, designated A through G, but only type A (BTX-
A) and B (BTX-B) are commercially available and used in
clinical practice. In 1989, the Food and Drug Administration
approved BTX-A for the treatment of strabismus; since
then, the growing use of this drug in several neurological
disturbances has made it one of the most important
advancements in the therapeutics of movement disorders
such as muscular dystonia and dyskinesia. At the same
time, botulinum toxin (BTX) either alone or adjunct to
other measures has emerged as a new important therapeutic
strategy for clinicians, treating a wide range of disturbances
including gastroenterological and urological diseases as well
as dermatological and cosmetic applications.
In the last decade, one of the main indications of
BTX is the treatment of disorders characterized by mus-
cular hyperactivity and excessive or inappropriate mus-
cle contraction. Neurorehabilitative medicine treats these
patients and ameliorates severe neurological impairments
that have scarcely available therapeutic interventions. This
paper presents both the consolidated applications of BTX
in spasticity as well as in other disturbances in which it has
been shown to be a useful therapeutic tool. Since in clinical
practice, BTX-B is less used than BTX-A, and few researches
studies have been published regarding its use, most of data
presented pertain to BTX-A treatment.
2. Structure and Type of BTX
The active BTX molecule is formed by two chains weighing
∼150.000daltons, in which a heavy chain is linked by a
disulﬁde bond to a light chain [1]. The heavy chain is2 Journal of Toxicology
responsible for neuron-speciﬁc binding and internalization.
Once internalized and within a vesicle, the light chain
across the vesicle membrane is released into the neuronal
cytoplasm,whereitbindstoaspeciﬁctargetproteininvolved
in the docking and fusion of acetylcholine-containing vesi-
cles to the internal portion of the cell membrane. These
target proteins are collectively referred to as the SNARE
complex. The BTX-A cleaves a protein termed SNAP-25,
whereas BTX-B binds a diﬀerent protein designed VAMP,
also known as synaptobrevin [2]. Both are responsible
for vesicle acetylcholine release. The derangement of this
process at the neuromuscular junctions cause clinical eﬀects
consisting in muscle weakness and paralysis. BTX-A and
BTX-B are commercially available and used in clinical
practice. To date, three formulation of BTX-A are com-
mercialized and are marketed as Botox (Allergan, Inc.,
Irvine, Calif, USA), Dysport (Ipsen Ltd., Berkshire, UK)
and Xeomin (Merz, Frankfurt, Germany), respectively. The
preparations are manufactured by diﬀerent processes, have
diﬀerent formulations and potencies, which are determined
by diﬀerent biological assays based on their clinical use.
BTX-B is marketed by Solstice Neuroscience (Malvern, Pa,
USA) as MyoBloc in the United States and NeuroBloc (Elan
Pharmaceuticals, San Diego Calif, USA) in Europe. It is
important to note that the potency of a single unit varies
greatly among the commercial types. Although the potency
of 1U of Botox is roughly equal to 1U of Xeomin, 3U of
Dysport, and 40 to 50U of MyoBloc, it is very important to
recognize that a simple ratio of dosing equivalencies cannot
be applied [3]. BTX-B is commercially packaged in vials of
10mL containing 5.000MU and 10.000MU of neurotoxin.
For muscle injections, botulinum toxins are diluted with
0.9% sodium chloride solution at variable volumes depend-
ing on the dose that the clinician plans to inject. BTX doses
are generally adjusted according to factors such as severity
of the hyperactive muscle, number of muscles involved, age,
and previous response to BTX therapy. The duration of BTX
eﬀect is variable depending from several factors including
type of neurotoxin, dose, site of injections, and clinical
applications. In disease botulism, neurotoxin A produces
longer paralysis than botulinum neurotoxin B consistent
with human observations [4]. Likewise, BTX-A has been
shown to have a longer duration of eﬀe c ti nc e rvi c a ld y s t o n i a
compared with BTX-B [5] .B o t u l i n u mt y p e sAa n dBh a v e
a similar duration of clinical action in treating drooling
due to neurological diseases [6]. In poststroke spasticity,
the duration of action was not speciﬁcally addressed by the
available studies although some trials suggested that eﬃcacy
of BTX-A may be appreciated 6 weeks after injection and for
upto9–12weeks[7].BTX-Bhasatendencytoproducemore
autonomic side eﬀects than BTX-A [8]a n dc a nh a v eam o r e
enduring action than BTX-A in speciﬁc clinical applications
such as hyperidrosis and sialorrhea [9, 10].
3.Spasticity
In a neurorehabilitation setting, BTX is predominantly used
for the treatment of spasticity and to prevent muscular
contractures. Spasticity is deﬁned as a velocity-dependent
increased resistance to passive limb movement in people
with upper motor neuron syndrome [11]. Clinically, it is
an involuntary motor disorder, characterized by hypertonic
muscle tone with increased excitability of the muscle stretch
reﬂex and increased tendon reﬂexes. Muscle weakness and
limb paresis are associated to spasticity and contribute to the
loss of motor dexterity and ability. Spasticity, if left untreated
can hamper functional outcome by promoting persistent
abnormal posture that, in turn, produces muscular-tendon
contractures and bone deformity. Secondary complications
arising from spasticity include impaired movement, hygiene,
self-care, poor self-esteem, body image, pain, and pressure
ulcers. Furthermore, patients with severe spasticity can
develop poor social participation and quality of life (QOL)
[12]. Because of these clinical concerns and related high
social costs [13], several therapeutic strategies have been
proposed for the treatment of spasticity including surgical,
medical, and rehabilitative procedures. However, spasticity
is not always harmful and patients with a combination of
muscle weakness and hypertonic muscles may rely on the
increased tone to maintain their posture and aid standing
or walking. It is important to point out that BTX use is
indicated when the spasticity is focal or segmental and if it
interferes with active or passive functioning. Treatment of
muscle hyperactivity may be considered when the condition
is disabling. The primary aim of the treatment of spastic
muscles is to maintain length and allow normal positioning
of the limbs to prevent secondary soft-tissue shortening.
Generally, BTX treatment is carried out as an adjunct to
otherrehabilitativestrategiesthatarebasedonanindividual-
ized, multidisciplinary programmes and targeted to achieve
patient goals. Treatment plans must consider a tradeoﬀ
between reduction of spastic hypertonia and preservation of
residual motor function [14].Althoughthereisnoconsensus
as to when BTX therapy should be initiated, or how long it
should last, BTX-A injection is considered the hallmark or
ﬁrst line of medical treatment for focal/segmental spasticity
[15]. Conversely, BTX-B has been predominantly used as
an alternative agent for patients who developed resistance
to BTX-A [16]. BTX-B has been used for the treatment of
adult and child spasticity, but its eﬀectiveness is unclear [17].
Data in the literature are insuﬃcient to recommend it for
the treatment of children with spasticity [18]. It is known
that spasticity can follow several neurological diseases such
as stroke, acquired brain injury, multiple sclerosis, cerebral
palsy, and spinal cord injury. BTX use for the treatment of
spasticity in some of those will be addressed.
3.1. Poststroke Spasticity. Spasticity is a frequent motor
disorder in adult patients with stroke and its incidence
is variable ranging from 17% to 43% [19–21]. A bulk of
trials have demonstrated the eﬃcacy of BTX-A in reducing
poststroke spasticity [22–24]. Improvement of hypertonic
muscles has been reported both in upper [12, 25–28]
and lower limbs [29–31] after BTX-A injections. Thus far,
administration modalities, and standard muscle doses of
BTX-A (either Botox or Dysport) have been proposed for
the reduction of limb spasticity in adult patients with stroke.Journal of Toxicology 3
However, there is no clear evidence from the literature to
guide optimal timing of interventions (e.g., early versus
late), frequency of interventions, dilutions, injection sites, or
doses. Current clinical recommendations for muscle-speciﬁc
dosing in spasticity remain largely based on expert opinion,
clinical experience, as well as the formulation of botulinum
toxin being used. A mean BTX-A global dose ranging from
90 to 360MU and from 350 to 1500MU per intramuscular
injection has been reported for upper spastic limbs when
using Botox or Dysport, respectively. A BTX-A dose ranging
from 100 to 400MU and from 400 to 1500MU for the
two toxins, respectively, has been used in treating lower
spastic limbs [7, 32]. According to the European Consensus
on the use of BTX-A in adult spasticity, maximum doses
should not exceed 1500MU Dysport and 600 MU Botox per
injection session [33]. The magnitude of response is dose
dependent [34, 35] even if the dosage is largely titrated by
the practitioner based on individual patient response.
BTX-B has also been used in treating poststroke spastic-
ity, but its eﬃcacy in reducing spasticity has been questioned
and,thusfarremainsunclear[17].Arecentsystematicreview
of BTX use in adult poststroke spasticity concluded that
available data on BTX-B were insuﬃcient to assess its eﬀect
on spasticity and that further controlled trials using BTX-B
were necessary [7].
Although the reduction of spasticity is widely demon-
strated with BTX-A treatment, its impact on the improve-
ment of dexterity and functional outcome remains contro-
versial. Some functional improvements may be seen after
BTX injections, but global functional assessment methods
do not consistently reﬂect these changes. Numerous studies
have reported to attain prespeciﬁed goals [26, 36], active
movement [37, 38], and gait [39]. Conversely, other studies
did not ﬁnd any beneﬁt on functional gain in patients
with post-stroke spasticity after BTX-A treatment [12, 40–
44]. Fridman et al. [45] reported kinematic parameters
improvement of spastic upper arm in post-stroke patients
after BTX-A injections. They speculated that the improve-
ment in velocity and time required to perform some
motor tasks could be translated to countless situations in a
patient’s life, which is diﬃcult to determine with objective
functional scales. Likewise, Bensmail et al. [44]d e s c r i b e d
improvement of kinematic parameters in upper spastic arm
after BTX-A treatment but without signiﬁcant changes in
clinicaloutcomes.However,clinicalpracticeshowsthatsome
patients beneﬁt with improved motor function, but that
predicting factors still have to be identiﬁed. Several reasons
have been suggested to explain this contrasting ﬁnding. It
is possible that spasticity does not contribute to limitation
of function and that the underlying weakness is the only
signiﬁcant cause of activity limitation [46]. Many recovering
patients with stroke experience signiﬁcant reductions in
functioning, QOL, and family relationships. Improvements
in QOL, caregiver burden, and patient functioning are key
measures of success in any rehabilitation program. Further-
more, these patients can develop shoulder pain that interfere
with the rehabilitative process and has been associated with
poorer outcomes and prolonged hospital stays [47]. BTX-A
treatment of poststroke spasticity has been demonstrated to
produce improvement of patients’ quality of life [12, 25]a n d
pain relief [48].
3.2. Spastic Cerebral Palsy. Cerebral palsy (CP) is the most
common nonprogressive cause of motor disturbance and
disability in children. Even with improvements in medical
technology and clinical practice, the overall rate of CP
remains high, with 2 to 3 per 1000 live births [49]. CP is
the main cause of spasticity in children. Therapeutic man-
agement may include splinting/casting, passive stretching,
facilitation of posture and movement, spasticity-reducing
medication, and surgery. Many clinicians frequently face the
dilemma of whether and how to medically treat spasticity
in children with CP. When pharmacologic intervention
is deemed appropriate, treatment decisions must ﬁrst be
based on accurate assessment using valid and reliable
clinical instruments, and, even more importantly, measur-
able, achievable, and realistic treatment goals should be
delineated. Successful use of BTX in children with CP was
ﬁrst reported in 1993 by Koman et al. [50]. Since then,
there has been a growing interest of the therapeutic eﬀects
of BTX-A, and many trials have investigated its eﬀectiveness
for treatment of spasticity in children and adults with CP
[18, 51–55]. Likewise in poststroke spasticity, BTX-A has
been eﬀective in the reduction of spasticity of both upper
[52, 56] and lower extremities [54, 57].
In the late 1990s, pediatric doses of BTX-A in the
treatment of children with spastic CP ranged from 12
to 16U/kg and from 15 to 25U/Kg of body weight for
Botox [58]a n dD y s p o r t[ 59], respectively. These dosages
have increased over time [60]. Higher BTX-A doses of
15 to 22U/kg and of 20 to 30U/kg have also been used
without serious adverse events for Botox [61] and Dysport
[62, 63], respectively. Maximum doses of BTX-A should
not exceed 300U Botox and 900U Dysport per injection
session, respectively. Children typically receive higher doses
per kilogram of body weight than adults and can develop
more adverse events. BTX-A treatment is eﬀective and safe,
maintaining long-lasting eﬀects after repeated injections. A
recent review of relevant literature concerning the treatment
of spasticity in children with CP recommended that the use
of BTX-A should be oﬀered as an eﬀective and generally
safe treatment to reduce localized/segmental spasticity in
upper and lower extremities. The same review did not ﬁnd
suﬃcient data to support or refute the use of BTX-B [18].
In this rehabilitation area, BTX-A is generally used as an
adjuncttophysiotherapyorotherrehabilitativeinterventions
such as casting or orthotics to obtain reduction of spasticity
and functional improvement. A review by Ryll et al. [54]
reported that BTX-A injections combined with usual care
or physiotherapy can have a positive eﬀect on walking in
children with CP. Trials comparing BTX-A with usual care
or physiotherapy showed evidence that functional outcomes
improved at diﬀerent follow-up times of 2 to 6 weeks [64,
65], 12 weeks [66], and 24 weeks [64, 66] when BTX-A
injections were combined with usual care or physiotherapy
compared to usual care or physiotherapy alone. Similarly,
another recent systematic review found a high level of
evidence supporting the use of BTX-A as an adjunct to4 Journal of Toxicology
managing upper limbs in children with spastic CP [56].
However, several issues remain unsolved including timing,
duration of BTX-A action, and its eﬀectiveness in the long
term. Furthermore, when BTX-A is used as adjunct to other
measures, the type of physiotherapy that is best indicated,
application, timing, and type of casting to obtain better
results remain unclear.
3.3. Brain Injury. About 75% of patients with physical
disabilityfollowingseverebraininjury(BI)willdevelopspas-
ticity requiring speciﬁc treatment. Also, patients with focal
spasticity due to BI can beneﬁt from BTX treatment. Unlike
poststroke spasticity, scarce data about the use of BTX in
treatingspasticityfollowingtraumaticBIhavebeenreported.
Generally, these studies used BTX-A and enrolled small or
heterogeneous samples of patients including subjects with
stroke and traumatic BI [67–70]. BTX-A injection was used
as an adjunct to physiotherapy [71] or casting [67]s tra t egi e s .
However, all studies demonstrated the eﬃcacy of BTX-A in
reducing spasticity either in adults [23, 67–70] or children
[71, 72].
4. BTX as Adjunct Therapy for
Management of Spasticity
Treatment of spasticity incorporating BTX is usually part
of an integrated multidisciplinary rehabilitation program.
BTX is rarely a sole treatment, and it is generally used
combined with physiotherapy or casting, particularly in chil-
dren with spastic CP. Physiotherapy procedures associated
with BTX-A treatment can be variable including stretching
posture, constraint induced therapy, occupational therapy,
and electrical stimulation [73–76]. A previously mentioned
systematic review reported that a combination of BTX-A
and occupational therapy for the treatment of spastic arm
in children with CP is more eﬀective than occupational
therapy alone in reducing impairment, improving activity
leveloutcomes,andgoalachievement[56].Furthermore,the
authors found a high level of evidence to support the use of
BTX-A as an adjunct to managing upper limb spasticity in
these children.
4.1. BTX and Casting/Orthotics. BTX is also used to prevent
muscular contraction and to facilitate cast application or
orthotics. Serial casting is a method used for reducing con-
tractures due to spasticity and can be applied both to upper
and lower limbs. BTX can facilitate this process by producing
temporary weakness and relaxation of the targeted muscles,
allowing them to be stretched more easily, thus reducing
the neurogenic and biomechanical components of spasticity.
Casting is the application of ﬁberglass and/or plaster to
the spastic upper or lower limb to immobilize a joint and
has been proposed for the treatment of spasticity following
stroke, acquired brain injury and CP, in particular. This
strategy has been recommended as a treatment option in
the management of equinus in children with CP for many
decades. Early researches reported that BTX is as eﬀective
as serial casting in improving dynamic function for children
suﬀering with cerebral palsy [77–79]. Hence, there has been
a growing interest of the therapeutic eﬀects of BTX-A as
adjunct to casting [80–82]. However, the eﬀect of BTX-A
combined with casting on the reduction of spasticity remain
controversial and unclear [53, 80–82]. A systematic review of
the eﬀects of the casting on equinus of children with CP did
not ﬁnd any diﬀerences between groups comparing BTX-A
plus casting or BTX-A alone versus casting [81].
Furthermore, similar questions and doubts about the
improvement of functional outcome were raised when BTX
and casting was used for the treatment of spastic children
with CP. Studies comparing BTX-A injections plus casting
or BTX-A injections alone versus casting showed strong
evidence for no eﬀects on the functional outcomes in the
application of BTX-A injections, casting alone, or a combi-
nation of both treatments [54] in children with CP. On the
other hand, Yas ¸ar et al. [82] recently observed that in chronic
stroke patients, casting might be an appropriate intervention
followingBTX-Ainjectiontopreventequinovarusdeformity
and to improve the quality of walking. Likewise, casting and
application of orthotics might potentiate the eﬀect of BTX
treatment. Lai et al. [83] reported that in poststroke spastic
patients, dynamic splinting after BTX injection increased the
range of active elbow extension and suggested that it might
be a useful adjunct procedure for optimizing BTX eﬀects.
5. BTX Use without Spasticity
Neurological diseases can produce variable and complex
impairments requiring tailored rehabilitation strategies. In
a neurorehabilitation setting, clinicians have to approach
numerous motor and nonmotor disorders other than spas-
ticity. BTX use in speciﬁc neurological diseases and disorders
with complex neurological dysfunction will be provided.
6.BTX andFocalHandDystonia
Focal hand dystonia (FHD) is a motor disturbance charac-
terized by a task speciﬁc muscle spasms, in which learned or
repetitive motor tasks (such as writing or playing a musical
instrument) trigger muscle spasms and interfere with prac-
ticedmotorexecution,whereasotheractionsremainnormal.
FHD include a variety of disorders aﬀecting many diﬀerent
skilled functions. Writer’s cramp and musician’s dystonia
are the most common forms of idiopathic FHD [84].
Writer’s cramp is characterized by involuntary, repetitive,
or sustained contractions of ﬁnger, hand, or arm muscles
that occur during writing and produce abnormal postures
or movements that interfere with normal handwriting.
Although the prevalence is relatively low, varying from 3
to 7/100000, [85, 86], it may be responsible for consid-
erable morbidity in terms of working impairment, pain,
embarrassment, low self-esteem, and poor social interaction.
Musician’s dystonia is a task-speciﬁc movement disorder
that manifests itself as a loss of voluntary motor control
in extensively trained movements. Approximately 1% of all
professional musicians develop musician’s dystonia, and in
many cases, the disorder terminates the careers of aﬀectedJournal of Toxicology 5
musicians [87]. Therapeutic strategy proposed for the
treatment of FHD including muscle relaxation techniques,
physical and occupational therapy, and medical and surgical
therapies have all been disappointing. Several researches
have demonstrated that BTX injections into selected hand
and forearm muscles provides the most eﬀective relief in
patients with these task-speciﬁc occupational dystonias [88–
90]. Injection of BTX into the muscles responsible for
the abnormal postures can be very eﬀective and is often
considered the ﬁrst choice. A muscle dose ranging from 5
to 40MU of BTX-A (Botox) and from 15 to 150MU of
BTX-A (Dysport) has been injected for writer’s cramp [91].
There has also been a speciﬁc study showing utility for
musician’s cramps [92]. Patients can continue to respond
to injections for many years. Lungu et al. recently reported
that BTX-A treatment was safe and eﬀective after more
than a decade of treatment [93] in 20 patients with FHD.
Of these, the musicians were more likely to wait longer
between injections. The dose of BTX is based on the size
of the muscle aﬀected, the intensity of the spasm, and
the number of muscles involved [94]. Likewise, in other
motor disorders, BTX can correct abnormal hand posture
and relieve discomfort. However, the restoration of normal
hand function can be diﬃcult to achieve. Not only are some
of the underlying dystonic defects, such as loss of speed
and coordination, not fully addressed by the botulinum
toxin injection, but the weakness that accompanies injection
can be an additional source of hand disability. In some
patients, the tradeoﬀ between disability due to weakness
from injection and disability due to the dystonia itself is not
acceptable. The cyclic improvement with BTX injection and
the worsening of the dystonia when the beneﬁt wears oﬀ,
does not allow for consistent sustained performance which
is especially problematic for professional musicians [95].
7.BTXandObstetricalBrachial PlexusInjury
Obstetric brachial plexus injury (OBPI) can be a dramatic
sequela of dystocia or complicated delivery. A recent study
showed an incidence of 1.3 per 1000 live births in the United
States [96]. A higher incidence, ranging from 3 to 4.6 per
1000livebirthswasfoundinEurope[97,98].Severebrachial
plexus palsies can result in disabling due to impairment
and imbalance of the muscular contraction in the paretic
limb. In spite of physical therapy, some children continue to
experience contractures and abnormal posture that hamper
complete recovery. In the last decade, an increasing number
of reports on the treatment of BTX-A for OBPI have
been published [99–103]. BTX-A has been used to improve
muscularimbalanceoftheinternalrotator-adductormuscles
of the shoulder, limited active elbow extension, and triceps
cocontraction in combination with conservative treatment,
including long-term physiotherapy, occupational therapy,
and functional orthopaedic or plastic surgery. Furthermore,
BTX-A as adjunct to serial casting has been successfully used
in children with OBPI to improve muscular contracture,
arm position, elbow extension, and dexterity in the paretic
limb [99, 100]. However, a recent systematic review about
the treatment indications of BTX-A in children with OBPI
emphasized the need for randomized controlled trials to
determine its beneﬁts and eﬃcacy in order to support the
continued use of this intervention in managing muscle
imbalance and muscle cocontraction in children with OBPI
[104].
8. BTX in Sialorrhea
Since BTX also inhibits the release of presynaptic acetyl-
cholineattheneurosecretoryjunctionsofthesalivaryglands,
it has been proposed as a possible eﬃcacious pharmaco-
logical treatment for hypersalivation and sialorrhea, which
can occur and complicate the course and management of
somesevereneurologicaldiseasessuchasamyotrophiclateral
sclerosis (ALS), Parkinson’s disease (PD), and CP. Indeed,
numerous studies have demonstrated that BTX-A and BTX-
Ba r ee ﬀective and safe for the reduction of drooling in
patients with ALS and PD [105–108]. The injected doses
into salivary glands is variable depending on the disease,
the BTX used, and the clinician’s experience. The mean
globaldosesinjectedintosalivaryglandsrangedfrom55Uto
200U (Botox) [109, 110] and from 250U to 450U (Dysport)
[111, 112] for BTX-A and from 2500 to 4000U for BTX-
B[ 106, 108, 113]. A recent research study comparing the
two toxins in controlling sialorrhea of ALS and PD patients
reported that either 250U BTX-A (Dysport) or 2500U BTX-
B (Neurobloc) have similar eﬀectiveness and safety [6].
In children with CP, drooling and sialorrhea have an
incidence of 10% to 37% [114]. These symptoms can have
a devastating eﬀect on the family’s social relationships and
thepatient’squalityoflife.Severalstudieshavedemonstrated
thatBTX-Acanbeusedwithsuccessincontrollingsialorrhea
in children with CP [115, 116]. A mean dose of BTX-A
(Botox) ranging from 2 to 22.5U/kg of body weight per
single gland has been injected [117–119]. BTX-B can also be
as a f ea n de ﬀective therapy for the treatment of drooling in
these children. A recent randomized trial comparing three
doses of 1500MU, 3000MU, and 5000MU BTX-B injection
into the salivary glands with ultrasound guidance [10]
reported that the 3000MU injection of BTX-B signiﬁcantly
improved the frequency and severity of sialorrhea in those
children. The lower dosage was ineﬀective, and the higher
dosage produced no greater beneﬁt and more side eﬀects. It
has been proposed that BTX-B is more eﬀective and could
have a more enduring eﬀect than BTX-A on autonomic
function [10, 106]. Indeed, autonomic side eﬀects are
sometimes observed far from the injection site (such as dry
mouth) after treatment for axillary hyperhidrosis with BTX-
B[ 120]. As previously mentioned, BTX-B has a tendency
to produce more autonomic adverse events than BTX-A
[5, 8, 121, 122], mainly due to the hypothesized aﬃnity for
postganglionic neurons containing M3 receptors (such as
those responsible for salivation) [123]. However, the study
of Guidubaldi et al. found that that BTX-B had a shorter
latency than BTX-A and comparable duration [6]. The most
relevant ﬁnding was that BTX-B had a signiﬁcantly shorter
latency than BTX-A (3 versus. 6 days). The diﬀerent latencies6 Journal of Toxicology
might be due to various characteristics of the two serotypes,
perhaps diﬀusion and/or aﬃnity for autonomic ﬁbers.
9.BTXUse inRareRehabilitative
ClinicalConditions
Neurologically disabled subjects can present with complex
dysfunction and clinicians have to face unique and diﬃcult
to treat clinical conditions. BTX can be a useful therapeutic
tool in some of these conditions. Anecdotal reports have
been published concerning the use of BTX-A in speciﬁc
rare conditions such as sustaining posture after surgery
in patients with cervical disk herniation, secondary to
dystonic cerebral palsy [124]. BTX-A has been used to
hasten the healing of lower lip ulcers due to oromandibular
dyskinesia in a subject in a vegetative state following a severe
subarachnoidhemorrhage[125].Likewise,BTX-Atreatment
was used to hasten the healing of a buttock pressure sore in
a subject with severe spastic paraplegia following a traumatic
spinal cord lesion. In this last case, several therapeutic agents
were applied without success, since all eﬀorts at healing the
ulcer by topical medication were hampered by recurrent
spasms involving the gluteal muscles and the ulcer region
[126]. Gluteal injections of 660U BTX-A (Dysport) reduced
the movement disorder and improved buttock ulcer healing.
10. Adverse Events
Before performing BTX-A injections for therapeutic pur-
poses, the expected risks and beneﬁts for each patient must
becarefullyconsidered.Currently,dosagesarelargelytitrated
by the practitioner based on the previously mentioned
criteria and the individual patient’s response. Reported
adverse events associated with BTX are infrequent and
predominantly concern the BTX-A formulation. Local and
remote eﬀects following BTX injections have been described.
The former consisted in a reaction at the injection site,
including pain, rush, and edema, whereas remote eﬀects
are due to diﬀusion of toxin and cause variable eﬀects
characterized by autonomic, regional, or systemic muscular
weakness. Most adverse events after BTX treatment arise
through weakness of the muscles injected or those nearby,
which become weak through local spread of the toxin.
Allergic or possible immune-mediated mechanisms have
been proposed to be the cause of symptoms such as general
malaise, fever, and skin rush.
Observedadverseeventsincludenausea,urinaryinconti-
nence, falls, seizures, fever, dry mouth, and dysphagia [127].
These disturbances have often been found in patients with
preexisting comorbidities, for example, seizures in subjects
with previous epileptic disorders. General malaise and “ﬂu-
like” symptoms have also been described [42]. Generally,
they are mild to moderate and transient. A pooled analysis
including 792 patients concluded that nausea was the most
frequent minor adverse event in poststroke patients treated
with BTX-A, aﬀecting 2.2% of cases [127]. No serious
adverse event was reported in a recent systematic review
regarding BTX-A use in adults with poststroke spasticity
[7]. Conversely, because children receive higher doses per
kilogram than adults, they can develop more adverse events.
A variable incidence of side eﬀects ranging from 4% to
7% has been reported [40, 128, 129]. In a previously
mentioned paper, 28.5% of CP children who were injected
with5000MUofBTX-Bforsialorrheadevelopedgeneralized
weakness and severe dysphagia requiring hospitalization and
nasogastric tube feeding [10]. A very infrequent systemic
eﬀect manifested was generalized weakness distant from the
site of injection [130] .Ar e c e n tr e v i e wo fc a s e sd e s c r i b e d
in the literature indicates that risk of developing systemic
eﬀects does not seem to be related to dose based on body
weight [131]. It may be more likely that risk for this
condition is related to the total injection dose and injection
frequency.Dosesgreaterthan600unitsofBotoxwithfollow-
up injections occurring every 3 months may lead to an
increased risk of developing severe adverse events. Repeated
contralateral weakness and fatigue after high doses of BTX-
A injection for poststroke spasticity have been also described
[132].
11. Neutralizing Antibodies
BTX-A eﬀects can be abolished by the development of
neutralizing antibodies (NAbs). Antibody formation against
BTX proteins is one of the reasons for therapy failure.
Studies have demonstrated that antibodies-binding toxins,
speciﬁcally in the region responsible for entry into neurons,
neutralize or inactivate the toxin. In order to overcome
therapy failure, injecting increased BTX doses with short
injection intervals and using diﬀerent BTX serotypes [133,
134] has been suggested. This phenomenon is reported with
a variable incidence according to the treated disorder. In
cerebral palsy, the incidence of NAbs has been reported
in a range from 6% to 31% [128, 135, 136]. NAbs are
rare in poststroke spasticity. In a sample of 235 poststroke
patients with spasticity receiving a dose ranging from
100 to 400 MU of BTX-A, Yablon et al. [137]f o u n d
<0.5% of NAbs. The development of NAbs are facilitated
if repeated injections and high dosages of BTX are used
independently from the treated disorder. However, NAbs are
morefrequentinpatientswithcervicaldystoniacomparedto
other hyperactive muscular disturbances. The development
of NAbs has been also observed in subjects who underwent
BTX injections for nonmotor disorders such as sialorrhea.
Although no BTX-A resistance in the treatment of sialorrhea
has yet been reported, this disappointing phenomenon has
recently been described for BTX-B after repeated injection
into the salivary glands [138].
12. Considerations
Muscle selection is a key feature for the eﬃcacy of BTX
treatment,andtheinﬁltrationmodalitiesareafurthersource
of heterogeneity. BTX-A injections are more eﬃcacious if
the muscles are targeted by needle EMG or ultrasound
guidance. There is evidence from dystonia that EMG
targeting increases accuracy and improves outcome [139].Journal of Toxicology 7
However, when high doses are injected into suﬃciently
large muscles, as in spasticity, toxin diﬀusion compensates
for this limitation. Salivary glands are generally injected
by ultrasound guidance. A drawback for BTX therapy is
its high cost and the transient nature of the toxin. In this
respect, recent papers have reported that the clinical beneﬁts
of BTX-A treatment outweigh the apparent high costs of
this intervention, showing it to be a cost-eﬀective treatment
[13, 42].
13. Conclusions
Botulinum toxin types A and B are valuable agents in the
multiple therapeutic strategies that clinicians carry out in
a neurorehabilitation setting. It is important to strive to
attain the best clinical and functional beneﬁt that improves
the quality of care of patients undergoing rehabilitation.
Since neurologically disabled subjects present complex dys-
function, prior to initiating BTX therapy, speciﬁc functional
limitations, goals, and expected outcomes of treatment
should be discussed with the patient and caregiver. Muscle
selection and the order and priority of treatment should
be tailored to the treatment of spasticity and muscular
imbalance. BTX-A and BTX-B strategies should be viewed as
adjunct measures based on the individual’s residual ability,
and competence and tailored rehabilitation programs are
needed to achieve the best functional outcome. Although
BTX-A treatment has been demonstrated safe and eﬀective
in managing several neurological disorders, many questions
still remain unsolved. Future studies should address if
this agent alone or as an adjunct to other rehabilitative
procedures optimizes functional outcome.
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